



ASX / MEDIA RELEASE

17<sup>th</sup> March 2016

## **Selective Internal Radiation Therapy (SIRT) Granted Reimbursement in the Netherlands**

**Sydney, Australia; 17<sup>th</sup> March 2016** – Sirtex Medical Limited (ASX:SRX) today announces the Netherlands Healthcare Institute, Zorginstituut Nederland (ZIN), has agreed to reimburse Selective Internal Radiation Therapy (SIRT) for patients with colorectal liver metastases who have failed or are intolerant to prior chemotherapy. The ZIN based its decision on clinical evidence of the efficacy and safety of SIR-Spheres<sup>®</sup> Y-90 resin microspheres for treating this patient group.

“This announcement is very good news for the many patients in the Netherlands with liver metastases from colorectal cancer who have previously received chemotherapy and biological treatments,” said Dr Marnix Lam, Nuclear Medicine Physician at University Medical Center Utrecht.

Ms Gerda Schapers, a survivor of advanced metastatic colorectal cancer and a board member of The Dutch Intestinal Cancer Foundation stated, “I am delighted that patients from all over the Netherlands can now benefit from this innovative therapy, with which I was treated more than three years ago.”

Mr Gilman Wong, CEO of Sirtex Medical commented, “We are delighted the Netherlands Healthcare Institute has recognised the established safety and efficacy of SIR-Spheres microspheres in this patient population, which will lead to more patients seeking treatment at leading specialist centres across the Netherlands. We continue to engage with government bodies throughout the EMEA region as part of our strategy to increase the availability of our innovative therapy to patients living with liver cancer. We anticipate this could lead to an expansion in the reimbursement offered for SIR-Spheres microspheres over time.”

A new patient registry to collect and analyse treatment data on the first 500 patients with colorectal liver metastases who receive SIRT under the new reimbursement programme has also been established.

SIR-Spheres microspheres will be made available to patients in the Netherlands through 10 specialist centres. Sirtex anticipates reimbursed dose sales in the Netherlands will commence during the current half. Colorectal cancer is the third most common cancer in the Netherlands, with an annual incidence of approximately 14,000 cases and accounts for around 5,200 deaths each year.<sup>1</sup>

### **About Colorectal Cancer**

Colorectal cancer (CRC or bowel cancer) occurs when cancerous cells develop in the patient’s colon or rectum. CRC is the third most common form of cancer worldwide, making up about 10% of all cancers. In 2012, an estimated 1.4 million new cases were diagnosed globally and 694,000 cancer deaths were attributed to CRC.<sup>2</sup>

---

**Head Office**  
Level 33, 101 Miller Street  
North Sydney, NSW 2060  
Australia

**Americas**  
300 Unicorn Park Drive  
Woburn, MA 01801  
United States

**Europe, Middle East & Africa**  
Josef-Schumpeter-Allee 33  
53227 Bonn  
Germany

**Asia Pacific**  
50 Science Park Road, #01-01  
The Kendall Science Park II  
Singapore 117406

## **About SIR-Spheres® Y-90 Resin Microspheres**

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

## **About Sirtex Medical**

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Approximately 61,000 doses have been supplied to treat patients with liver cancer at more than 950 medical centres in over 40 countries. For more information please visit [www.sirtex.com](http://www.sirtex.com).

For further information please contact:

### **Investor Enquiries:**

Mr Gilman Wong  
CEO  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8400

Dr Tom Duthy  
Global Investor Relations Manager  
Sirtex Medical Limited  
Phone: +61 (0) 2 9964 8427  
Email: [tduthy@sirtex.com](mailto:tduthy@sirtex.com)

### **Media Enquiries:**

Tim Allerton or Andrew Geddes  
City PR  
Phone: +61 (0) 2 9267 4511

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

---

<sup>1</sup> Globocan 2012. Estimated cancer mortality, incidence and prevalence worldwide. Available at: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_population.aspx](http://globocan.iarc.fr/Pages/fact_sheets_population.aspx)

<sup>2</sup> World Cancer Report, 2014; Geneva, WHO: 2014; 1.1.